About CraniUS
CraniUS is a company based in Baltimore (United States) founded in 2021 by Chad Gordon. CraniUS has raised $39.5 million across 4 funding rounds from investors including Maryland.gov, Mumbai Angels and Lumis Partners. CraniUS offers products and services including NeuroPASS. CraniUS operates in a competitive market with competitors including Impel NeuroPharma, Cognos Therapeutics, Cordance Medical, PassPort Technologies and Bionxt, among others.
- Headquarter Baltimore, United States
- Founders Chad Gordon
- SectorsHealthcare
- Email••••••••
- Website craniustherapeutics.com
- Social LinkedIn X YouTube
- Total Equity Funding$39.5M (USD)
in 4 rounds
- Latest Funding Round$19M (USD), Series B
Jan 2026
- InvestorsMaryland.gov
& 2 more
Products & Services of CraniUS
CraniUS offers a comprehensive portfolio of products and services, including NeuroPASS.
Skull-implantable device for targeted brain disease treatment and drug administration.
Apps and channels of CraniUS
its YouTube channel CraniUS Therapeutics has 12 subscribers.
Funding Insights of CraniUS
CraniUS has successfully raised a total of $39.5M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $19 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $39.5M
- Total Rounds 4
- Last Round Series B — $19M
- First Round $500,000
(Aug 2021)
- Investors Count 3
All 4 funding rounds of CraniUS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $19M | Series B | – | – | – |
| Jun 2024 | $1M | Grant | – | – | |
| Sep 2022 | $20M | Series A | – | – | – |
| Aug 2021 | $500,000 | Seed | – | Mumbai Angels |
3 investors in total: 3 institutional.
Investors in CraniUS
CraniUS has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Maryland.gov, Mumbai Angels and Lumis Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage venture investments are facilitated by Mumbai Angels network. | 2006 | mumbaiangels.com | Mumbai, India | |
Investment in alternative assets, businesses, and funds in India. | 2006 | lumispartners.com | Gurugram, India | |
Access to government programs and development services is facilitated. | – | maryland.gov | United States |
Investor details for CraniUS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CraniUS
6 people are tracked at CraniUS (5 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Chad Gordon | Founder & CMO | Leadership |
Michael Maglin | CEO | Leadership |
Natalie Wisniewski | CTO & CPO | Leadership |
Jack Kent | VP, Strategy & Operations | Leadership |
Joshua Schaefer | Senior Director Of Product Development And Manufacturing | Leadership |
Judy Gonzalez | Marketing And Communications Strategist | Team |
Complete people profiles for CraniUS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CraniUS
3 dated milestones of CraniUS across 5 years, from founding to its latest funding, stage changes and deals.
- Founded CraniUS is founded.
- Funding First funding round of $500K.
- Funding Latest funding round, Series B, of $19.0M.
Competitors of CraniUS
CraniUS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Impel NeuroPharma, Cognos Therapeutics, Cordance Medical, PassPort Technologies and Bionxt, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| impelnp.com | 2008 | Seattle, United States | $126.83M | 158 | Intranasal delivery technology for CNS diseases is developed. | |
| cognosthx.com | 2015 | Los Angeles, United States | $5.75M | 13 | Cognos Therapeutics is focused on innovative neurological and oncological treatments. | |
| cordancemedical.com | 2018 | Mountain View, United States | – | – | Non-invasive ultrasound device for blood-brain barrier is developed. | |
| passport-tech.com | 2019 | San Diego, United States | – | – | Transdermal drug delivery systems are developed using microporation technology. | |
| bionxt.com | 2018 | Vancouver, Canada | – | 49 | Drug formulations and delivery systems for diseases are developed. | |
| nsgene.dk | 1999 | Ballerup, Denmark | $5.14M | – | Specializes in drug delivery systems and therapeutics for central nervous system diseases. | |
| palyonmedical.com | 2004 | New York, United States | $24M | – | Develops implantable drug delivery systems for central nervous system disorders. | |
| sinontx.com | 2015 | Durham, United States | – | – | Nanoparticle-based drug delivery platform for neurological diseases is developed. | |
| release-tx.com | 2023 | Geneve, Switzerland | $3.88M | – | Encapsulated cell therapy devices for CNS diseases are developed. |
Detailed competitors of CraniUS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cranius
Complete news archive for CraniUS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to CraniUS
10 companies that operate in the same segment as CraniUS (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CraniUS
CraniUS was founded in 2021.
CraniUS is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Michael Maglin is the current CEO of CraniUS.
CraniUS is a funded company, having raised a total of $39.5M across 4 funding rounds to date. The company's 1st funding round was a Seed of $500K, raised on Aug 2021.
CraniUS was founded in 2021 in Baltimore, United States, as a medical technology company. Implantable devices are developed by the company for brain tumor treatment and to address disorders such as Alzheimers and Parkinsons. The flagship product, NeuroPASS, is designed to deliver medication directly to the brain, bypassing the blood-brain barrier with controlled flow rates. Operations focus on innovative drug delivery solutions within the neurotherapeutics sector.
CraniUS's top competitors include Impel NeuroPharma, Cognos Therapeutics and Cordance Medical.
CraniUS offers NeuroPASS.
CraniUS has 3 investors. Key investors include Maryland.gov, Mumbai Angels, and Lumis Partners.